---
title: "GLP-1 Begins in the Gut: Clinical Clues From Microbiome Testing"
description: Gut bacteria shape GLP-1 secretion through short-chain fatty acids and bile acid signaling, and stool testing may reveal microbial clues to hormone output.
---

[Evidence-based Wellness Education](https://www.casi.org/articles)

# [GLP-1 Begins in the Gut: Clinical Clues From Microbiome Testing](https://www.casi.org/articles/glp-1-gut-microbiome-testing)

 Written by [Rachel B. Johnson, MS, CNS, LDN](https://www.casi.org/articles/author/rachel-b-johnson-ms-cns-ldn) | Aug 19, 2025, 12:00:00 PM

Glucagon-like peptide-1 (GLP-1) has gained significant attention in recent years for its role in metabolic health. Pharmaceutical GLP-1 receptor agonists (GLP-1 RAs) have demonstrated notable effects on appetite regulation, glycemic control, and body weight. However, far less clinical focus has been placed on the body’s natural ability to produce GLP-1 endogenously, a process that begins not in the pancreas, but in the gut.

This gut-based origin highlights the intricate relationship between GLP-1 and the gastrointestinal (GI) ecosystem. Notably, a growing body of research underscores the role of the gut microbiota in modulating [GLP-1 secretion through short-chain fatty acids (SCFAs)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266401/) like butyrate and propionate, and through [bile acid signaling pathways involving TGR5 and FXR receptors](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full).

These insights offer a powerful clinical implication: GLP-1 secretion is not fixed, it is influenced by microbial diversity, mucosal function, and immune activity. For practitioners, this means that stool-based, non-invasive gut microbiome functional wellness testing may provide valuable clues to assess and promote healthy GLP-1 physiology. 

## Physiology of Endogenous GLP-1 Production

[GLP-1 is synthesized and secreted by enteroendocrine L-cells](https://www.mdpi.com/2076-2607/10/10/2061), primarily located in the distal ileum and colon, in response to nutrient intake, [microbial metabolites, and gut-immune signals](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full). While macronutrient intake, particularly carbohydrates, proteins, and dietary fats, serves as a primary stimulus for GLP-1 release, L-cell activity is also [shaped by the metabolic byproducts of microbial fermentation](https://www.mdpi.com/2076-2607/10/10/2061), bile acid signaling, gut epithelial integrity, and [immune tone](https://www.mdpi.com/2076-2607/10/10/2061). [SCFA production and bile acid signaling](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full) represent two of the most well-characterized ways in which the gut microbiota influences [GLP-1 secretion through receptor-mediated pathways and mucosal interactions](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full).

## Microbial Mechanisms Modulating GLP-1

***SCFA Signaling***

[Short-chain fatty acids](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266401/), particularly butyrate and propionate, are generated through the [fermentation of dietary fibers and resistant starches](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266401/) by specific colonic bacteria. These SCFAs help promote and [activate GLP-1 secretion by binding to free fatty acid receptors FFAR2 (GPR43) and FFAR3 (GPR41)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266401/) located on L-cells. In addition to promoting GLP-1 physiology, SCFAs support [appetite regulation, metabolic signaling, and gut-brain communication](https://www.medrxiv.org/content/10.1101/2022.11.22.22282645v2.full-text). Thus, [reduced SCFA-producing microbes](https://www.medrxiv.org/content/10.1101/2022.11.22.22282645v2.full-text), often observed in individuals with [low microbial diversity or diets lacking fermentable fiber](https://www.medrxiv.org/content/10.1101/2022.11.22.22282645v2.full-text), may influence GLP-1 signaling and reduce microbial support for enteroendocrine function.

[Butyrate](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1067647/full) also serves as a [key energy source for colonic epithelial cells](https://www.mdpi.com/1420-3049/26/3/682) and supports epithelial barrier integrity by [promoting tight junction protein expression](https://www.mdpi.com/1420-3049/26/3/682) and [modulating local immune signaling](https://www.mdpi.com/1420-3049/26/3/682). These actions contribute to the gut’s ability to support healthy GLP-1 signaling.

***Bile Acid/L-Cell Crosstalk***

In addition to SCFAs, [secondary bile acids play a complementary role](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full) in modulating GLP-1 secretion. When gut microbes [convert primary bile acids into secondary forms](https://www.tandfonline.com/doi/full/10.1080/19490976.2023.2172671?scroll=top&needAccess=true#d1e249) such as deoxycholic acid and [lithocholic acid](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full), these metabolites can activate the [bile acid receptors TGR5 and FXR](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full) expressed on L-cells. [TGR5 activation](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full), in particular, has been shown to enhance GLP-1 release and [improve glucose homeostasis](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full).

The efficiency of this signaling process is dependent on the presence of bile acid-modifying microbes, including certain [species within the *Clostridium* and *Bacteroides* genera](https://www.tandfonline.com/doi/full/10.1080/19490976.2023.2172671?scroll=top&needAccess=true#d1e249). Disruptions in bile acid metabolism, often associated with [microbial dysbiosis or insufficient bile flow](https://www.tandfonline.com/doi/full/10.1080/19490976.2023.2172671?scroll=top&needAccess=true#d1e249), may therefore compromise GLP-1 stimulation via this pathway.

## *Interaction with L-Cells in the Gut *

The [density of L-cells increases along the GI tract](https://www.mdpi.com/2076-2607/10/10/2061), with the [highest concentrations found in the distal ileum and colon](https://www.mdpi.com/2076-2607/10/10/2061). These are the same regions most heavily colonized by [butyrate-producing microbes and bile acid-converting bacteria](https://www.mdpi.com/2076-2607/10/10/2061). This spatial relationship between microbial metabolic activity and L-cell abundance reinforces the concept that the gut microbiome plays an integral role in supporting healthy GLP-1 physiology.

In addition to nutrient and microbial stimuli, L-cell function is sensitive to [immune signals and epithelial integrity](https://www.mdpi.com/2076-2607/10/10/2061). Intestinal immune activation[, elevated lipopolysaccharide (LPS), or mucosal disruption](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full) may influence [L-cell density and GLP-1 output](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full). This underscores the importance of maintaining gut immune balance and barrier function in supporting hormone regulation.

## Gut Microbiome Functional Testing: Markers Relevant to GLP-1

Functional microbiome testing provides clinicians with a systems-level view of the GI ecosystem. These stool-based assays typically assess a range of domains, including microbial diversity, SCFA production potential, mucosal immune activity, digestive efficiency, and inflammatory response burden. While they are not direct measures of GLP-1 output, several of these markers can offer insight into a patient’s capacity for healthy GLP-1 secretion and gut hormone responsiveness.

### *Keystone Diversity*

[Microbial richness and keystone species diversity](https://www.mdpi.com/1420-3049/26/3/682) are foundational to gut ecosystem resilience. Reduced alpha diversity has been associated with [insulin resistance, elevated body weight](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2016.00154/full), and impaired [enteroendocrine signaling](https://www.mdpi.com/1420-3049/26/3/682). A robust and diverse microbiome fosters [metabolic crosstalk among taxa, enhances SCFA production, and supports anti-inflammatory signaling](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2016.00154/full), all of which influence GLP-1 dynamics.

Keystone species such as [*Faecalibacterium prausnitzii*](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1067647/full), [*Roseburia*](https://pmc.ncbi.nlm.nih.gov/articles/PMC8647967/)spp*.*, [*Anaerostipes*](https://journals.asm.org/doi/10.1128/msphere.00816-23)spp*.*, and [*Akkermansia muciniphila*](https://pmc.ncbi.nlm.nih.gov/articles/PMC11364076/) are especially important in maintaining mucosal health, producing fermentative metabolites, and stabilizing gut barrier function.

### *SCFA-Producing Flora*

Key SCFA-producing bacteria include [*Faecalibacterium*](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1067647/full), [*Roseburia*](https://pmc.ncbi.nlm.nih.gov/articles/PMC8647967/), and [*Anaerostipes*](https://journals.asm.org/doi/10.1128/msphere.00816-23). Reduced abundance of these organisms may correspond to [diminished fermentation capacity and lower support for GLP-1 physiology](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266401/). Testing that quantifies or semi-quantifies these organisms can help determine whether targeted dietary strategies or next-generation probiotics may be warranted.

### *Akkermansia and Anaerostipes: Notable Keystone Strains*

*Akkermansia muciniphila* is a [mucin-degrading bacterium that contributes to gut barrier integrity, helps regulate normal inflammatory responses, and modulates host metabolism](https://gut.bmj.com/content/gutjnl/65/3/426.full.pdf). Human and preclinical studies have shown that even [pasteurized, non-viable forms of *Akkermansia* can promote healthy insulin metabolism](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1370658/full) and [enhance GLP-1 secretion via TGR5-mediated signaling](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full). Its presence in the microbiome is considered a strong marker of mucosal health and metabolic flexibility.

[*Anaerostipes* spp*.* are lactate- and acetate-utilizing bacteria that convert these substrates into butyrate](https://journals.asm.org/doi/10.1128/msphere.00816-23), often in concert with other keystone species. This cross-feeding behavior allows *Anaerostipes* to play a [critical role in butyrate homeostasis and barrier protection](https://journals.asm.org/doi/10.1128/msphere.00816-23), particularly in fiber-fed or postbiotic-supported microbiomes. Although not widely available as a probiotic at present, clinical interest in *Anaerostipes* is growing as a precursor microbe involved with further butyrate production. Butyrate’s direct effects on [glycemic regulation and the promotion of microbial diversity](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1067647/full) further explain why *Anaerostipes* may support healthy GLP-1 production.

***Dysbiosis and LPS Burden***

Overrepresentation of opportunistic or potentially pathogenic organisms (such as *Klebsiella*, *Citrobacter*, *Clostridium difficile*, and *Candida* spp.) can [drive intestinal inflammation and increase luminal LPS exposure](https://www.mdpi.com/2076-2607/10/10/2061). LPS is known to suppress GLP-1 secretion by [impairing gut barrier integrity and triggering systemic inflammatory responses](https://www.mdpi.com/2076-2607/10/10/2061). Functional testing that identifies overgrowth patterns can help guide the rebalancing of the microbiome.

***Barrier and Immune Markers***

Markers such as secretory IgA (SIgA), calprotectin, and beta-glucuronidase provide insight into gut mucosal health and immune activity. Elevated calprotectin or [low SIgA may indicate active inflammation or immune suppression](https://www.science.org/doi/10.1126/sciimmunol.ade2335), both of which can [reduce L-cell viability and GLP-1 output](https://www.mdpi.com/2076-2607/10/10/2061). These markers, when evaluated alongside microbial profiles, offer a fuller picture of the intestinal environment and its capacity to support hormone signaling.

## Clinical Applications: Translating Stool Testing into GLP-1-Supportive Care

Functional microbiome testing offers practitioners a valuable lens into the gut environment. When interpreted with GLP-1 physiology in mind, test results can guide highly personalized strategies to support endogenous GLP-1 production. Interventions can be organized across three primary domains: diet, lifestyle, and targeted supplementation. Each intervention should be selected based on an individual’s functional stool profile, clinical presentation, and clinical timeline.

### *Dietary Interventions*

Nutritional strategies that enhance microbial fermentation, support SCFA production, and promote bile acid metabolism can directly influence L-cell signaling. Practitioners may consider the following:

- Prebiotic fibers ([partially hydrolyzed guar gum \[PHGG\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC10017317/), inulin, resistant starch) support SCFA-producing bacteria such as [*Anaerostipes*](https://journals.asm.org/doi/10.1128/msphere.00816-23) and [*Faecalibacterium*](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1067647/full).
- Polyphenol-rich foods (pomegranate, berries, green tea) [promote beneficial species such as *Akkermansia* and help support microbial diversity](https://gut.bmj.com/content/gutjnl/65/3/426.full.pdf).
- Minimizing ultra-processed foods, excessive refined sugars, and saturated fats helps [reduce inflammatory dysbiosis, lower LPS burden](https://www.mdpi.com/1420-3049/26/3/682), and create an environment more conducive to GLP-1 secretion.

### *Lifestyle Strategies*

Behavioral interventions can amplify the effects of dietary changes by supporting circadian rhythm alignment, gut-brain signaling, and microbial resilience:

- Time-restricted eating and circadian-aligned meal timing have been associated with [improvements in GLP-1 pulsatility and appetite regulation](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00082/full).
- [Regular physical activity](https://pmc.ncbi.nlm.nih.gov/articles/PMC11547208/), particularly resistance training and moderate aerobic exercise, [enhances microbial diversity and SCFA production](https://pmc.ncbi.nlm.nih.gov/articles/PMC11547208/), and has been linked to improved gut barrier integrity.
- Stress modulation techniques, including breathwork, [mindfulness, and parasympathetic activation](https://pmc.ncbi.nlm.nih.gov/articles/PMC7219460/), help reduce corticotropin-releasing hormone (CRH)-mediated suppression of gut hormone release and preserve L-cell function.

### *Targeted Supplementation*

In cases where test results indicate low microbial fermentation capacity, dysbiosis, or bile acid signaling disruption, targeted nutraceuticals may play a supportive role:

- [Butyrate donors (sodium butyrate, tributyrin)](https://onlinelibrary.wiley.com/doi/10.1111/obr.13498) support colonocyte energy metabolism and GLP-1 signaling.
- [Polyphenol blends](https://pmc.ncbi.nlm.nih.gov/articles/PMC10967430/) (pomegranate extract, grape seed extract, green tea catechins) may help promote microbial balance by [promoting *Akkermansia* abundance](https://pmc.ncbi.nlm.nih.gov/articles/PMC10967430/), a healthy inflammatory response, and supporting epithelial function.
- [Berberine](https://www.worldscientific.com/doi/10.1142/S0192415X24500113?rfr_dat=cr_pub++0pubmed&rfr_id=ori:rid:crossref.org&url_ver=Z39.88-2003), [digestive bitters](https://pmc.ncbi.nlm.nih.gov/articles/PMC8072924/#sec8-nutrients-13-01317), and [taurine](https://pmc.ncbi.nlm.nih.gov/articles/PMC10613769/) may help promote GLP-1 stimulation through the [cytoprotective effects on L-cells](https://www.worldscientific.com/doi/10.1142/S0192415X24500113?rfr_dat=cr_pub++0pubmed&rfr_id=ori:rid:crossref.org&url_ver=Z39.88-2003), the [mitigation of oxidative stress](https://pmc.ncbi.nlm.nih.gov/articles/PMC10613769/), and by [stimulating bile flow and secondary bile acid pathways](https://pmc.ncbi.nlm.nih.gov/articles/PMC8072924/#sec8-nutrients-13-01317).
- [Next-generation probiotics](https://www.casi.org/articles/next-generation-probiotics-anaerostipes-akkermansia), such as [pasteurized *Akkermansia muciniphila*](https://pmc.ncbi.nlm.nih.gov/articles/PMC10967430/) and fiber-fed [*Anaerostipes*](https://journals.asm.org/doi/10.1128/msphere.00816-23) spp., may offer clinically relevant support for microbial keystone restoration and hormone physiology.

## Conclusion

Supporting normal endogenous GLP-1 production through microbiome support reflects an emerging paradigm in personalized nutrition and GI health. The body’s ability to produce GLP-1 is shaped by factors such as SCFA production, bile acid transformation, gut barrier status, and microbial diversity.

Functional gut microbiome testing offers practitioners a valuable opportunity to assess these factors in a clinically meaningful way. By analyzing specific microbial patterns, inflammatory markers, and digestive signatures, providers can identify underlying contributors to impaired GLP-1 signaling and implement targeted interventions that support gut hormone physiology.

**To learn more about dietary, botanical, and lifestyle interventions in incretin health: **

[Foundations of GLP-1 Support: Nutritional and Lifestyle Strategies for Healthy Glucose Metabolism](https://www.casi.org/articles/foundations-of-glp-1-support-nutritional-and-lifestyle-strategies-for-healthy-glucose-metabolism)

[GLP-1s and Hydration: What You Need to Know](https://www.casi.org/articles/glp-1s-and-hydration-what-you-need-to-know)

[Two Next-Generation Probiotics You Should Know About: *Anaerostipes* and *Akkermansia*](https://www.casi.org/articles/next-generation-probiotics-anaerostipes-akkermansia)

[4 Surprising Botanicals to Promote Normal GLP-1 Production](https://www.casi.org/articles/4-surprising-botanicals-promote-normal-glp-1-production)

[View full post](https://www.casi.org/articles/glp-1-gut-microbiome-testing)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Rachel B. Johnson, MS, CNS, LDN"
  },
  "dateModified" : "2026-09-17T14:11:29.356Z",
  "datePublished" : "2025-08-19T12:00:00Z",
  "headline" : "GLP-1 Begins in the Gut: Clinical Clues From Microbiome Testing",
  "image" : {
    "@type" : "ImageObject",
    "height" : 605,
    "url" : "https://51358820.fs1.hubspotusercontent-na1.net/hubfs/51358820/casi/archive/aug-19-glp-gut.jpg",
    "width" : 1080
  },
  "mainEntityOfPage" : "https://www.casi.org/articles/glp-1-gut-microbiome-testing",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60.0,
      "url" : "https://51358820.fs1.hubspotusercontent-na1.net/hubfs/51358820/casilogoresize2-2.png",
      "width" : 147.05882
    },
    "name" : "CASI.org"
  }
}
```